42LOW

TRI

TRIVARX FPO [TRI]
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Mount Lawley, Australia.
Healthcare · ASX Small Cap
$0.0170 +13.3%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical57
Catalyst50
Sentiment50
Fundamental45
Momentum67
Risk Gate35
Get alerts when TRI's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track TRI — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic just turned bullish from a low level — early reversal sign
  • Lagging the Small Ords index — relative strength of 0.76, underperforming its peers
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Strong cash runway (13 quarters)
  • 4C filed 2026-01-29
  • Revenue in sharp decline (-100%)
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 92% over the past year (excluding last month)
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.15%/day)
  • Pre-revenue company — Altman Z-Score not applicable
  • Penny stock risk ($0.017)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -100% — the top line is shrinking
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about TRI
"What's driving TRI's score?" "How does TRI compare to peers?" "Key risks for TRI?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Key management changes
NONE Appendix 4D & Half-Year Financial Report to 31 December 2025
LOW December 2025 Quarterly Activities Report and Appendix 4C

Recent ASX Announcements

2026-03-04 Key management changes
2026-02-24 Appendix 4D & Half-Year Financial Report to 31 December 2025 PRICE SENSITIVE
2026-01-29 December 2025 Quarterly Activities Report and Appendix 4C PRICE SENSITIVE

Key Metrics

$19.6M
Market Cap
1.2M
Avg Volume
1.8x
Vol Ratio
$0.01 — $0.04
52-Week Range
0.0%
Short Interest
13 qtrs
Cash Runway
-12.1%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 78%
LLeader vs LaggardlaggardRS: -3
IInstitutional SponsorshipweakInst: 7%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #83 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:TRI vs ATXTRI vs PNVTRI vs IMM
Scout Pro — Deeper Analysis for TRI
Try Pro free for 30 days
Share this analysis

Track TRI and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required